The need for faster, more reliable environmental air monitoring is becoming increasingly critical as the number of new drug therapies requiring production in controlled environments continues to rise
Current monitoring technologies do not readily distinguish externally introduced sampling contamination from microbial contaminants captured from the clean room air systems.
This can cause delays in microbiological analysis due to false positives, resulting in loss of both time and money.
To resolve this problem, Pall is bringing its Ascotec environmental air monitoring systems to the global market so that biopharmaceutical companies can increase the predictability and accuracy of microbial samples, for the highest level of speed, safety and reliability.
